Skip to main content
. 2015 Oct 29;2(6):e166. doi: 10.1212/NXI.0000000000000166

Figure 2. Clinical outcome after extended follow-up.

Figure 2

The clinical outcome was measured using the modified Rankin Scale (mRS) at 0, 3, 6, 9, 12, 18, and 24 months after the onset of NMDA receptor (NMDAR)–antibody (Ab) encephalitis in immunoglobulin A (IgA)–NMDAR-Ab-positive (A) and IgA-NMDAR-Ab-negative (B) patients.